Key regulatory milestones and financial updates position Sangamo Therapeutics Inc (SGMO) for potential growth despite funding ...

RICHMOND, Calif., November 12, 2024 -- ( BUSINESS WIRE )--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial ...

13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader ... Research & Development and Head of Boston Roche Innovation ...

primarily due to their Genentech agreement, leading to a net income of $10.7 million compared to a loss in the previous year. Strategic developments include the submission of an IND application for a ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...

Specifically, I will discuss the acquisition of Dermavant Sciences Ltd., a Roivant Sciences Ltd. (ROIV) company, with a focus ...

Many actual events and circumstances are beyond our control. These forward-looking statements are subject to a number of risks and uncertainties, including those relating to: the ability of the ...

The Hillsboro Herald regularly tracks the happenings at Hillsboro City Hall, at least to the best of our ability we ...

NEW YORK — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics ...